Sheela Talwalker

Torrey Pines Institute For Molecular Studies — United States

Medicine · Health Sciences

12h-index1.5kcitations33works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(9), Statistical Distribution Estimation and Applications(6), Dementia and Cognitive Impairment Research(5), Anesthesia and Pain Management(4), Health Systems, Economic Evaluations, Quality of Life(4)

Publications33 total

Analysis of RNA recovery and gene expression in the epidermis using non-invasive tape stripping
Journal of Dermatological Science·2006· 29 cited
Valdecoxib, a Cyclooxygenase-2-Specific Inhibitor, Is Effective in Treating Primary Dysmenorrhea
Obstetrics and Gynecology·2002· 15 cited
Valdecoxib does not impair platelet function
The American Journal of Emergency Medicine·2002· 90 cited
The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery
The Journal of the American Dental Association·2002· 120 cited
Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects
The American Journal of Gastroenterology·2002· 81 cited
Parecoxib sodium effectively treats post-laparotomy pain.
Fertility and Sterility·2001· 4 cited
The cyclooxygenase (COX)-2 specific inhibitor valdecoxib effectively treats primary dysmenorrhea.
Fertility and Sterility·2001· 3 cited
The Injectable Cyclooxygenase-2-Specific Inhibitor Parecoxib Sodium Has Analgesic Efficacy When Administered Preoperatively
Anesthesia & Analgesia·2001· 136 cited
Parecoxib sodium demonstrates opioid sparing effects in post-laparotomy surgical patients.
Fertility and Sterility·2001· 5 cited
Parecoxib Sodium does not Impair Platelet Function in Healthy Elderly and Non-Elderly Individuals
Clinical Drug Investigation·2001· 87 cited
An endoscopic study of the gastroduodenal effects of SC-69124A, a parenteral COX-2-specific inhibitor, in the elderly
Gastroenterology·2000· 9 cited
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
Arthritis & Rheumatism·1998· 477 citedOpen Access
Long-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality
Birkhäuser Boston eBooks·1997· 3 cited
Long-term tacrine (Cognex) treatment
Neurology·1996· 295 cited
Cardinal Features of Cognitive Dysfunction in Alzheimer's Disease: A Factor-Analytic Study of the Alzheimer's Disease Assessment Scale
Journal of Geriatric Psychiatry and Neurology·1996· 26 cited
The use of survival analysis techniques in evaluating the effect of long-term tacrine (cognex<sup>®</sup>) treatment on nursing home placement and mortality in patients with
Journal of Biopharmaceutical Statistics·1996· 16 cited
Analysis of repeated measurements with dropouts among alzheimer's disease patients using summary measures and meta-analysis
Journal of Biopharmaceutical Statistics·1996· 9 cited
The cardinal features of cognitive and noncognitive dysfunction and the differential efficacy of tacrine in alzheimer's disease Patients
Journal of Biopharmaceutical Statistics·1996· 10 cited
P35 Longitudinal study of cardinal features of cognitive dysfunction in alzheimer's disease
Controlled Clinical Trials·1995
Qualitative and quantitative assessment of the risk from the exposure to fetotoxic chemical compounds
Environmental and Ecological Statistics·1995· 4 cited
page 1 of 2Next →

Frequent Co-authors

Richard C. Hubbard(7), Michael E. Kuss(6), B. Raja Rao(6), Michael C. Snabes(4), David P. Recker(3), D Lecomte(3), Stephen Gracon(3), Gilbert Geis(2), David S. Knopman(2), Fraser Smith(2), Toni M. Hoover(2), S. Gracon(2), Paul J. Desjardins(2), Shobha Dhadda(2), Stephen E. Daniels(2), Kenneth M. Verburg(2), John E. Overall(2), Mandyam K. Srirama(2), Sarah Torri(2), Debasis Kundu(2)